Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea Suspends First Approved Gene Therapy Pending Component Discrepancy Probe

Executive Summary

South Korea’s first approved gene therapy has been suspended from sale in the country, while recruitment in an ongoing US Phase III program has been temporarily halted, after findings that an active cell component may differ from the data submitted at the time of approval. While both manufacturer and regulator see no safety risk, results from an official Korean probe are due in mid-April.

You may also be interested in...

Gene Therapy Manufacturing Make-Or-Buy Options Weighed

Once a gene therapy product begins to show promise in clinical trials, the next step is deciding how the product is to be manufactured. Options are to make the product in house, contract out the manufacturing, or to combine the two approaches. An industry representative discussed some of the advantages and disadvantages of each approach and what to look for in the site selection process if the company decides to build out.

Disease Modifying Status Targeted As Kolon's Novel OA Therapy Enters US Phase III

With the removal of an FDA clinical hold, Kolon TissueGene is set to begin a US Phase III trial for Invossa, its first-in-class cell and gene therapy, for osteoarthritis of the knee. The planned study, which is larger and longer than the product's Korean Phase III program, will be under the spotlight as it will determine whether Invossa can be designated as the world's first disease-modifying drug in osteoarthritis, and is being designed accordingly.

First Approval For Kolon's Invossa But No Disease-Modifying Status

Kolon Life Science's Invossa gets regulatory approval in South Korea as the world's first allogeneic cell-mediated gene therapy for degenerative osteoarthritis, but misses out on disease-modifying status, although the company hopes a large-scale Phase III study can rectify this in the US.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts